Bortezomib: Understanding the mechanism of action

Molecular Cancer Therapeutics

Volumn 10, Issue 11, 2011, Pages 2029-2030

  Piperdi, Bilal ^a   Ling, Yi He ^a   Liebes, Leonard ^b   Muggia, Franco ^b   Perez Soler, Roman ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PEMETREXED; PROTEASOME; PROTEIN BCL 2; UBIQUITIN;

APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TUMOR LEVEL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; HUMANS; MULTIENZYME COMPLEXES; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; TOSYLPHENYLALANYL CHLOROMETHYL KETONE;

EID: 81055124278     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0745     Document Type: Short Survey

References (11)

1. Ling Y-H, Liebes L, Perez-Soler R, et al. PS-341, a novel proteosome inhibitor, induces bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-9.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22. (Pubitemid 29269108)
3. Investigator's Brochure Millennium Pharmaceuticals, Inc. VELCADE*(bortezomib) for Injection (Edition 10). 2011
4. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11. (Pubitemid 34856332)
5. Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade ((R))) in chemotherapy-naïve patients with advanced stage nonsmall cell lung cancer (NSCLC). Lung Cancer 2009 Jun 11.
6. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, et al.; Southwest Oncology Group. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 2009;4:87-92.
7. Fanucchi M, Fossella F, Belt R, Natale R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5025-33 (Pubitemid 46631406)
8. Lynch TJ, Fenton D, Hirsh V, Bodkin D, Middleman EL, Chiappori A, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2009;4:1002-9.
9. Scagliotti GV, Germonpré P, Bosquée L, Vansteenkiste J, Gervais R, Planchard D, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010;68:420-6.
10. Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, et al. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 2011;12:33-7.
11. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel Proteasome Inhibitors to Overcome Bortezomib Resistance. J Natl Cancer Inst 2011;103:1007-17.